Clinical Chemistry Podcast · Association for Diagnostics and Laboratory Medicine

Toward Improved Prostate Cancer Screening: Insights from the Göteborg-2 Trial

·25 min

The episode stays focused on prostate cancer screening and the tradeoff at the center of it. On one side is the appeal of finding aggressive disease early; on the other is the harm of finding too many low-risk cancers that lead to biopsy and treatment without much benefit. PSA is the starting point. The show makes the case that PSA screening is sensitive, but the follow-up it creates can expose men to unnecessary procedures when the disease is clinically insignificant. Digital rectal examination comes up briefly, but only briefly. Later studies have not shown a real screening role for the rectal exam, so it does not add much here. MRI is the newer tool that gets the most attention. Lilje describes how the G2 randomized screening trial in Goteborg used MRI after an elevated PSA to narrow who should be biopsied and to focus sampling on suspicious lesions. The trial design is the important part. One arm followed the older approach of systematic biopsy, with 10 to 12 cores taken across the prostate and extra cores added if MRI showed something suspicious. The comparison is tighter in the other arm. There, MRI alone decided whether biopsy happened at all, and sampling was directed only at the lesion seen on imaging. The episode keeps coming back to why that matters. The goal is not just to find more cancer, but to tilt the balance toward the dangerous cases while cutting down on overdiagnosis and the downstream harms of overtreatment. The first trial readout gets a mention as well. The conversation points to earlier reporting from 2022 and newer results in the New England Journal of Medicine, while making clear that the evidence is still developing. Mortality is hard to use as the only endpoint. The show notes that widespread PSA testing has already lowered prostate cancer mortality across Western countries, which makes it harder for newer trials to show a clean extra survival effect. The uncertainty is left in place. The episode ends on the practical question of how screening can become more selective without losing sight of the men who most need early treatment.

As heard by us

MRI helps narrow prostate screening by reducing unnecessary biopsies and overdiagnosis.

It treats prostate cancer screening as a tradeoff, not a slogan: catch the dangerous cases early, but do not turn every PSA bump into a biopsy or a cascade of treatment for low-grade disease.

Read the full review in PlayNext →

Why you'd press play

Press play if you want the MRI-versus-biopsy tradeoff explained without clinical fog.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify